
|Videos|March 15, 2011
Vandetanib Advantages in Medullary Thyroid Cancer
Author(s)Peter Langmuir, MD
Advertisement
Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
3
INDEPENDENCE, Type II JAK Inhibitor Data Highlight Key MPN and AML Data Arriving at EHA 2026
4
Unanswered Questions and the Role of ctDNA Dynamics in Selecting Intensification Candidates in EGFR-Mutant NSCLC
5






































































